Trials / Recruiting
RecruitingNCT07231419
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 734 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Suzetrigine | Tablets for oral administration |
| DRUG | Placebo (matched to SUZ) | Placebo matched to SUZ for oral administration. |
Timeline
- Start date
- 2025-11-21
- Primary completion
- 2027-04-06
- Completion
- 2027-04-06
- First posted
- 2025-11-17
- Last updated
- 2026-04-13
Locations
55 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07231419. Inclusion in this directory is not an endorsement.